The efficacy of tazemetostat for the treatment of malignant lymphoma has been validated in phase I and II studies [96,97], and a phase II study of tazemetostat showed high efficacy for follicular lymphoma with both wild-type and mutant EZH2 mutations [97]. Here, EZH2 is linked to lymphoma.